Bruker vs Revvity
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Bruker and Revvity side by side, using each one’s latest annual report. Here is what stands out:
- Bruker is the larger business, with $3.4B of revenue in fiscal 2025 against $2.9B for Revvity.
- Revvity grew revenue faster (3.7%, against 2.1%).
- Revvity kept more of each dollar of sales as operating profit (12.5% operating margin, against 2.0%).
- Revvity turned more of its sales into free cash flow (17.8% FCF margin, against 1.3%).
- Revvity earned a higher return on the capital invested in it (3.3%, against 0.9%).
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Bruker
BRKR
1/10
5-year growth
Revvity
RVTY
9/10
Revenue growthOperating marginNet marginFCF marginReturn on capitalReturn on equityPiotroski F-scoreNet debt / EBITDAShare count change
Side by side
Best in the row
| Latest fiscal year | BRKR FY25 | RVTY FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.9B | $17.9B |
| Revenue | $3.4B | $2.9B |
| Free cash flow | $43.3M | $509M |
| Net income | −$8.6M | $241M |
| Growth | ||
| Revenue growth | 2.1% | 3.7% |
| 5-year growth | 11.6% | −5.5% |
| Share count change | 1.5% | −5.1% |
| Profitability | ||
| Gross margin | 45.9% | — |
| Operating margin | 2.0% | 12.5% |
| Net margin | −0.3% | 8.5% |
| FCF margin | 1.3% | 17.8% |
| Return on capital | 0.9% | 3.3% |
| Return on equity | −0.4% | 3.2% |
| Balance sheet | ||
| Net debt | $1.6B | $2.3B |
| Net debt / EBITDA | 5.5x | 3.0x |
| Dividends and buybacks | $32.8M | $854M |
| Valuation & quality | ||
| P/E | — | 76.7x |
| Piotroski F-score | 4 | 5 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.